The incidence of acute urinary retention secondary to BPH is increasing among California men

Prostate Cancer and Prostatic Diseases

Volumn 16, Issue 3, 2013, Pages 260-265

  Groves, H K ^a,b   Chang, D ^a,c   Palazzi, K ^a   Cohen, S ^a   Parsons, J K ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO HEALTH SYSTEM   (United States)

Author keywords

a blocker; BPH; five a reductase inhibitor; incidence; lower urinary tract symptoms; urinary retention

Indexed keywords

ACUTE URINARY RETENTION; ADULT; AGE; AGED; ARTICLE; ASIAN; CONTROLLED STUDY; DISEASE ASSOCIATION; EMERGENCY WARD; HEALTH INSURANCE; HISPANIC; HUMAN; INCIDENCE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RACE DIFFERENCE; RISK ASSESSMENT; TREND STUDY; UNITED STATES; URETHRAL CATHETERIZATION; URINE RETENTION;

AGED; AGED, 80 AND OVER; CALIFORNIA; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA; RISK; URINARY CATHETERIZATION; URINARY RETENTION;

EID: 84882448705     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2013.11     Document Type: Article

References (27)

1. Saigal CS, Joyce G. Economic costs of benign prostatic hyperplasia in the private sector. J Urol 2005; 173: 1309-1313.
2. Wei JT, Calhoun E, Jacobsen SJ. Urologic diseases in America project: benign prostatic hyperplasia. J Urol 2005; 173: 1256-1261.
3. Engstrom G, Henningsohn L, Steineck G, Leppert J. Self-assessed health, sadness and happiness in relation to the total burden of symptoms from the lower urinary tract. BJU Int 2005; 95: 810-815.
4. Taylor BC, Wilt TJ, Fink HA, Lambert LC, Marshall LM, Hoffman AR et al. Prevalence, severity, and health correlates of lower urinary tract symptoms among older men: the MrOS study. Urology 2006; 68: 804-809.
5. Parsons JK, Mougey J, Lambert L, Wilt TJ, Fink HA, Garzotto M et al. Lower urinary tract symptoms increase the risk of falls in older men. BJU Int 2009; 104: 63-68.
6. Kupelian V, Fitzgerald MP, Kaplan SA, Norgaard JP, Chiu GR, Rosen RC. Association of nocturia and mortality: results from the Third National Health and Nutrition Examination Survey. J Urol 2011; 185: 571-577.
7. Armitage JN, Sibanda N, Cathcart PJ, Emberton M, van der Meulen JH. Mortality in men admitted to hospital with acute urinary retention: database analysis. BMJ 2007; 335: 1199-1202.
8. McConnell JD, Roehrborn CG, Bautista OM, Andriole Jr GL, Dixon CM, Kusek JW et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Eng J Med 2003; 349: 2387-2398.
9. Roehrborn CG, Siami P, Barkin J, Damiao R, Major-Walker K, Nandy I et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 2010; 57: 123-131.
10. Parsons JK. Commentary on BPH and public health-have we lost the forest through the trees? J Urol 2008; 179(5 Suppl): S81.
11. Stroup SP, Palazzi-Churas K, Kopp RP, Parsons JK. Trends in adverse events of benign prostatic hyperplasia (BPH) in the USA, 1998 to 2008. BJU Int 2012; 109: 84-87.
12. Cathcart P, van der Meulen J, Armitage J, Emberton M. Incidence of primary and recurrent acute urinary retention between 1998 and 2003 in England. J Urol 2006; 176: 200-204.
13. Izard J, Nickel JC. Impact of medical therapy on transurethral resection of the prostate: two decades of change. BJU Int 2011; 108: 89-93.
14. Wei JT, Miner MM, Steers WD, Rosen RC, Seftel AD, Pasta DJ et al. Benign prostatic hyperplasia evaluation and management by urologists and primary care physicians: practice patterns from the observational BPH registry. J Urol 2011; 186: 971-976.
15. Miner MM. Primary care physician versus urologist: how does their medical management of LUTS associated with BPH differ? Curr Urol Rep 2009; 10: 254-260.
16. Sung JC, Curtis LH, Schulman KA, Albala DM. Geographic variations in the use of medical and surgical therapies for benign prostatic hyperplasia. J Urol 2006; 175(3 Pt 1): 1023-1027.
17. Abelson R, Creswell J, Palmer G. Medicare Bills Rise as Records Turn Electronic. New York Times The New York Times Company: New York, 2012.
18. Abelson R, Creswell J. U.S. Warning to Hospitals on Medicare Bill Abuses. New York Times. The New York Times Company: New York, 2012.
19. Stephenson A, Seitz D, Bell CM, Gruneir A, Gershon AS, Austin PC et al. Inhaled anticholinergic drug therapy and the risk of acute urinary retention in chronic obstructive pulmonary disease: a population-based study. Arch Intern Med 2011; 171: 914-920.
20. Woldrich JM, Palazzi-Churas K, Lakin C, Albo M, Parsons JK. Prostate laser vaporization in men with urinary retention. BJU Int 2011; 108: 395-398.
21. Kashefi C, Messer K, Barden R, Sexton C, Parsons JK. Incidence and prevention of iatrogenic urethral injuries. J Urol 2008; 179: 2254-2257.
22. Leuck AM, Wright D, Ellingson L, Kraemer L, Kuskowski MA, Johnson JR. Complications of foley catheters-is infection the greatest risk? J Urol 2012; 187: 1662-1666.
23. Platz EA, Kawachi I, Rimm EB, Willett WC, Giovannucci E. Race, ethnicity and benign prostatic hyperplasia in the health professionals follow-up study. J Urol 2000; 163: 490-495.
24. Van Den Eeden SK, Shan J, Jacobsen SJ, Aaronsen D, Haque R, Quinn VP et al. Evaluating racial/ethnic disparities in lower urinary tract symptoms in men. J Urol 2012; 187: 185-189.
25. Howard DL, Taylor YJ, Ross LE. Differences in lower urinary tract symptoms, treatment and mortality among African-American and white elderly men. J Natl Med Assoc 2008; 100: 1146-1152.
26. Parsons JK. Modifiable risk factors for benign prostatic hyperplasia and lower urinary tract symptoms: new approaches to old problems. J Urol 2007; 178: 395-401.
27. Sarma AV, Parsons JK, McVary K, Wei JT. Diabetes and benign prostatic hyperplasia/lower urinary tract symptoms-what do we know? J Urol 2009; 182(6 Suppl): S32-S37.